inhibitor

(redirected from nucleoside reverse transcriptase inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
See: deterrent
References in periodicals archive ?
Separately, the company signed an agreement with Yamasa Corporation based in Choshi, Japan, to develop EFdA (4 -ethynyl-2-fluoro-2 -deoxyadenosine), a novel nucleoside reverse transcriptase inhibitor candidate that is in preclinical studies and has shown antiviral activity toward highly resistant HIV strains.
Separately, the company signed an agreement with Yamasa Corporation based in Choshi, Japan, to develop EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine), a novel nucleoside reverse transcriptase inhibitor candidate that is in preclinical studies and has shown antiviral activity toward highly resistant HIV strains.
They then added nevirapine (Viramune) and at least 1 nucleoside reverse transcriptase inhibitor (NRTI).
Nucleoside reverse transcriptase inhibitors (NRTIs) have been used to boost antiviral efficacy when constructing antiretroviral (ARV) regimens for patients with virologic failure.
There are no clinically significant pharmacokinetic interactions between nucleoside reverse transcriptase inhibitors (NRTIs) and rifampicin-based TB treatment.
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients The SMART/INSIGHT and DAD Study Groups AIDS, 2008, 22, F17-F24
The survey, which looked at specimens from 3,130 newly diagnosed, drug-naive individuals, found that 4% of infections had mutations conferring resistance to nucleoside reverse transcriptase inhibitors, 7% to nonnucleoside reverse transcriptase inhibitors, and 2% to protease inhibitors.
Human Immunodeficiency Virus HIV Protease Inhibitors HIV Non-nucleoside Reverse Transcriptase Inhibitors HIV Nucleoside Reverse Transcriptase Inhibitors HIV Entry Inhibitors HIV Integrase Inhibitors Hepatitis C Virus Protease Inhibitors HCV Polymerase Nucleoside Inhibitors Other HCV Inhibitors Respiratory Syncytial Virus Inhibitors Influenza, Hepatitis B, and Cytomegalovirus Inhibitors
These results show that the investigational, long acting, injectable formulations of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen) were comparable in maintaining viral suppression rates to a three drug oral regimen of investigational cabotegravir and two nucleoside reverse transcriptase inhibitors (NRTIs).

Full browser ?